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INTRODUCTION
In this chapter, we discuss issues regarding BP management
and the use of BP-lowering drugs in CKD patients that are
currently the subject of ongoing research or controversy and
for which there is insufficient evidence upon which to base a
recommendation at this time.
8.1: ASSESSMENT OF BP
The RCTs on which this Guideline is based involved standard
office BP measurements, with the exception of the ESCAPE
trial in children.14 In clinical practice BP assessment typically
involves measurements made in the clinic or ‘office.’ In RCTs,
the protocols for BP measurement usually require one or
more BP readings taken after a period of rest and avoiding
prior activities that may have effects on BP. As far as it is
possible these protocols should be followed in clinical
practice if this evidence is used to guide management. The
techniques for office BP measurement and associated
problems are well described in the hypertension litera-
ture.10,143,401 There is no reason to believe that office BP
measurement should be performed differently in CKD
patients than in non-CKD patients, other than a strong
emphasis be placed on measuring supine or sitting and
standing BP because of the increased likelihood of orthostatic
hypotension associated with volume depletion, autonomic
neuropathy, older age, and drug effects.44,45,374,375
Measuring BP in the general community and in particular,
patients with ‘essential’ hypertension, is becoming increasingly
sophisticated. Examples include technologies that assess ‘usual’
BP as distinct from the BP measured at an office visit and new
ways of measuring BP, beyond just systolic and diastolic
pressures. Gradually, these advances are being implemented in
research and BP management in CKD patients.
Ambulatory BP monitoring and self-monitoring at home.
There is a long history of assessing BP by means other than
the BP measurement taken at an office visit. The ‘gold
standard’ is automated ABPM, the techniques for which have
been well described,10,143,401 and self-monitoring using
automated devices, which is increasingly used. Recommen-
dations and guidelines for the use of ABPM and self-
monitoring are accumulating in the hypertension literature
(Table 4).
There have been a limited number of studies conducted in
CKD patients but data suggest that in CKD, high ABPM
systolic pressures, and nocturnal ‘non-dipping’ (i.e., the
absence of a drop in BP during sleep) are associated with
increased risks of mortality (as in other populations) and of
decline in GFR or kidney failure.11,77,78 As has been found for
non-CKD patients, office BP measurements are commonly
overestimates (in the case of white-coat hypertension) or
underestimates (in the case of masked hypertension) of
‘usual’ BP when compared with ambulatory BP assessments.
A recent paper highlights the interest in ABPM in CKD.79
436 hypertensive CKD patients were prospectively followed
using ABPM and this was shown to be much more accurate
in predicting both renal and cardiovascular outcomes than
office BP. White coat hypertension was common, and ABPM
indicated that non-dipping and reverse dipping of nocturnal
BP were particularly predictive of cardiovascular and renal
outcomes. Future trials are needed to assess the best means of
measuring BP in CKD patients by randomizing patients to
ABPM, home BP or office BP directed therapy and to address
whether evening dosing to encourage ‘dipping’ is advanta-
geous as recently demonstrated in non-CKD hypertensive
individuals.80,81
Given the technical and economic barriers to routine
measurement of ambulatory BP, self-BP recording using
automated BP devices has been introduced because these give
readings that are more in line than with ABPM than those
achieved by office BP measurements.12,402,403
Self-BP measurement and ABPM are being used increas-
ingly in BP management and the devices for measuring them
usually rely on oscillometric assessment of BP at the elbow.
Atrial fibrillation and very high pulse pressures can lead to
inaccuracies and hence, re-calibration against traditional
methods of BP measurement is important.402 While it is
unlikely that self-BP monitoring or ABPM will become part
of mainstream CKD montoring in developing countries in
the near future, they are likely to become more widely used if
further research indicates the value of these techniques in
CKD management.
Measurement of pulse pressure and pulse wave velocity.
The stiffening of arterial walls that accompanies CKD (as well
as aging and chronic high BP) causes a loss of the volume
compliance in the large arteries such as the aorta, reducing
their ability to effectively buffer the systolic pressure wave
generated by the left ventricle and thus resulting in higher
systolic BP. In diastole, the loss of elastic recoil leads to a
reduced diastolic pressure. These changes together contribute
to a higher pulse pressure and faster pulse wave velocity, since
the pulse wave travels more rapidly when the larger arteries
are less compliant. Measurement of pulse pressure or pulse
wave velocity can therefore offer insights into vascular
structure and function.32,373 Studies of pulse pressure or
chapte r 8 http://www.kidney-international.org
& 2012 KDIGO
382 Kidney International Supplements (2012) 2, 382–387
Table 4 | Existing guidelines on ambulatory BP monitoring (ABPM) and home BP monitoring
Society or authors Measurement recommendations
British Hypertension
Society406
Home BP monitoring:
Accuracy of at-home recordings can be improved by calibration of the home instrument with a known standard, but even so, a lower
threshold for treatment is recommended (i.e., less than 135/85mmHg) because of inaccuracies in home measurements and the
tendency for home readings to be lower than office readings.
ABPM:
Recommended levels of normality for ambulatory BP
BP levels (mmHg)
Optimal Normal Abnormal
Daytime o130/80 o135/85 4140/90
Nighttime o115/75 o120/70 4125/75
Japanese Society of
Hypertension Guidelines
for self-monitoring of BP
at home407
Home BP monitoring:
1. Arm-cuff devices based on the cuff-oscillometric method that have been validated officially and the accuracy of which has
been confirmed in each individual should be used for home BP measurement.
2. The BP should be measured at the upper arm. Finger-cuff devices and wrist-cuff devices should not be used for home BP
measurements.
3. Devices for home BP measurement should be adapted to the American Association for Medical Instrumentation standards
and the British Hypertension Society guidelines. In addition, the difference between the BP measured by the auscultatory
method and the device should be within 5mmHg in each individual. The home measurement device should be validated
before use and at regular intervals during use.
4. Home BP should be monitored under the following conditions: The morning measurement should be made within 1 h after
waking, after micturition, sitting after 1 to 2min of rest, before drug ingestion, and before breakfast. The evening
measurement should be made just before going to bed, sitting after 1 to 2min of rest.
5. Home BP should be measured at least once in the morning and once in the evening.
6. All home BP measurements should be documented without selection, together with the date, time, and pulse rate. Use of
devices with a printer or an integrated circuit memory is useful to avoid selection bias.
7. The home BP in the morning and evening should be averaged separately for a certain period. The first measurement on
each occasion should be used for totaling.
8. Home BP values averaged for a certain period Z135/80mmHg indicate hypertension and Z135/85mmHg, definite
hypertension. Normotension is defined as less an average BP o125/80mmHg and definite normotension as
o125/75mmHg.
American Society of
Hypertension408
ABPM: Ambulatory BP monitors measure BP by means of auscultatory or oscillometric methods. Auscultatory monitors use a microphone
on the bladder cuff to detect the Korotkoff sounds. The advantage of this technique is that arm movement does not interfere with the
recording; however, these monitors are sensitive to background noise. Oscillometric monitors sense arterial pressure vibrations and
calculate systolic and diastolic values using an algorithmic approach. They are unaffected by background noise, but arm movement can
cause errant readings. Both types of monitors are validated by the British Hypertension Society and the Association for the Advancement of
Medical Instrumentation. Patients wear the monitor for a 24-hour period, usually a workday. The monitor is preprogrammed to record BP,
usually every 15 to 20minutes during daytime hours and every 20 to 30minutes during night-time hours. Patients are instructed to keep an
activity log throughout the testing period for evaluation of stress- and activity-related BP changes.
Pickering et al.409 ABPM: Currently available ambulatory monitors are fully automatic and can record BP for 24 hours or longer while patients go about
their normal daily activities. Most monitors use the oscillometric technique. They can be worn on a belt or in a pouch and are
connected to a sphygmomanometer cuff on the upper arm by a plastic tube. Subjects are asked to keep their arm still while the cuff is
inflating and to avoid excessive physical exertion during monitoring. The monitors are programmed to take a reading every 15 to
30minutes throughout the day and night. At the end of the recording period, the readings are downloaded into a computer. Standard
protocols are used to evaluate the accuracy of the monitors, and approved devices are usually accurate to within 5mmHg of readings
taken with a mercury sphygmomanometer. The daytime level of ambulatory BP that is usually considered the upper limit of the normal
range is 135/85mmHg.
The Seventh Report of the Joint
National Committee
on Prevention, Detection,
Evaluation, and Treatment
of High Blood Pressure143
ABPM is warranted for evaluation of white-coat hypertension in the absence of target-organ injury. It is also helpful in patients with
apparent drug resistance, hypotensive symptoms with antihypertensive medications, episodic hypertension, or autonomic dysfunction.
Ambulatory BP values are usually lower than office readings. Individuals with hypertension have an average BP of 4135/85mmHg
when awake and 4120/75mmHg during sleep. The level of BP measurement by using ABPM correlates better than office
measurements in patients with target organ injury. ABPM also provides data on the percentage of BP readings that are elevated, the
overall BP load, and the extent of BP reduction during sleep. In most individuals, BP decreases by 10 to 20% during the night; those in
whom such reductions are not present are at increased risk for cardiovascular events.
Home BP monitoring: Home measurement devices should be checked regularly for accuracy.
European Society of
Hypertension337,401,403
1. Refers to http://www.dableducational.org/ for UK available ABPM and home measuring devices.
2. Details proper equipment and technique.
3. Outlines accepted and potential clinical indications for ABPM.
NICE Guideline117 Out-of-office BP measurements are now recommended as part of the proper diagnosis of hypertension. ABPM should be offered to
confirm the diagnosis of hypertension if two BP measurements during an office consultation are X140/90mmHg. If ABPM is used, at
least two measurements per hour must be taken during waking hours (08:00 to 22:00). The average value at least 14 measurements
taken during the waking hours is needed to confirm the diagnosis of hypertension.
Home BP monitoring is a suitable alternative to ABPM and requires two consecutive BP measurements a minute apart in the seated
position, taken twice daily (usually morning and evening) for at least 4 days (but ideally 7). The first day’s measurements are discarded
and the average of the remaining measurements are used to confirm a diagnosis of hypertension.
Stage 1 hypertension is diagnosed if average BP from ABPM or home monitoring is Z135/85mmHg. When using ABPM or home BP
monitoring to assess response to treatment, the target average BP during waking hours should be o135/85mmHg for people aged
under 80 years and o145/85mmHg for people aged Z80 years.
ABPM, ambulatory blood pressure monitoring; BP, blood pressure.
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pulse wave velocity have been widely performed in the
general, hypertensive, and diabetic populations as well as to a
limited extent, in hemodialysis patients, in whom the
correlation of pulse wave velocity with mortality has been
well documented.32,35
Pulse wave velocity may be increased in early CKD34,404,405
but it is unclear what this means in terms of CVD risk and
kidney-disease prognosis. It is also unclear whether treatment
of BP will alter pulse wave velocity in the longer term for
CKD 1-5 patients and if so, whether this might influence the
prognosis. While sophisticated studies such as pulse wave
velocity are unlikely to become widespread in the global CKD
community, especially in less economically advanced com-
munities, further research is likely to lead to better use of this
tool for assessment of BP related changes in the cardiovas-
cular system in CKD patients and possibly to treatment
changes based on pulse wave velocity indices.
8.2: IS THERE AN EVIDENCE-BASED LOWER LIMIT FOR BP
REDUCTION?
The Work Group discussed whether it would be preferable to
recommend a target range (lowest to highest) for BP rather
than just a single target for highest acceptable BP. Although
the benefits of lowering BP in CKD have been demonstrated,
allowing us to recommend that we should aim for BP consis-
tently r140/90mmHg when albumin excretion is o30mg
per 24 hours and r130/80mmHg if albumin excretion is
Z30mg per 24 hours in both non-diabetic (Chapter 3) and
diabetic (Chapter 4) adults with CKD ND, we were unable to
give any recommendations for a lower BP target level due to a
lack of evidence.
There are observational data that support the intuitive
notion that excessive BP reduction might be harmful, at least in
trials that have not specifically recruited CKD patients. In a
cohort of 4071 very elderly (Z80 years) ambulatory American
veterans (hence 96.6% males) with hypertension on 1.7±1.2
(mean±SD) antihypertensive medication classes, a J-shaped
survival curve was noted when the relationship between both
systolic and diastolic pressure and survival was examined. The
optimum survival was associated with the ranges of diastolic
BP between 70–79mmHg and systolic BP between 130-
139mmHg.43 In another smaller study (n¼ 331) of mortality
with 2 year follow-up in elderly hospitalized subjects470 years
with vascular disease or hypertension, the longest survival was
observed when diastolic BP was in the range 71–80mmHg, with
a pronounced increase in risk with diastolic BPr60mmHg.410
Further evidence to discourage aggressive reduction in BP
in high risk groups comes from secondary analyses of
outcomes associated with achieved BPs in the context of large
RCTs. Such analyses are retrospective in nature and the trials
themselves have not specifically recruited (and often
excluded) patients with reduced GFR, so they cannot be
used to formulate a guideline for a lower BP target in the
context of CKD. One example of such a study is a
retrospective analysis of the active treatment group of the
SHEP trial. In this study, 4736 subjects agedZ60 years with a
systolic BP 4160mmHg and diastolic o90mmHg were
randomized to placebo or BP reduction with chlorthalidone
with or without atenolol to reduce systolic BP. Perhaps
surprisingly, a low diastolic BP on treatment was associated with
an increased risk of stroke, coronary heart disease and CVD.41
Likewise in INVEST, a multi-national RCT comparing verapamil
sustained-release and atenolol-based treatment in 22,576 patients
with hypertension and CAD, BP control and outcomes were
equivalent between the groups, but the risk of the primary
outcome (all-cause death, non-fatal myocardial infarction and
non-fatal stroke) progressively increased with a BP lower than
119/84mmHg, although taken alone, stroke risk did not increase
with lower BP. After adjustment for multiple variables the
relationship between low diastolic BP and primary outcome
persisted.40 Further analysis of the above association including
only the 2699 patients with peripheral artery disease also showed
a J-shaped relationship, such that the primary outcome occurred
least frequently at a systolic BP of 135-145mmHg and a diastolic
BP of 60-90mmHg, with the effect most strongly related to
systolic BP.411 Stratifying patients into those aged o60, 60 to
o70, 70 to o80 and Z80 years and plotting survival versus
diastolic BP produced a pronounced J-curve effect with a HR
nadir at 75mmHg up to 80 years, then 70mmHg for subjects
480 years. For systolic BP the HR nadir increased with
increasing age: 115mmHg up to 70 years, 135mmHg for
70 to o80 years, and 140mmHg for Z80 years.42
In ONTARGET involving 25,588 patients with athero-
sclerotic disease or diabetes with organ damage, a J-shaped
relationship between on-treatment systolic BP (nadir around
130mmHg) and all outcomes except stroke was observed in a
retrospective analysis.412 Data from IDNT showed that a
systolic BP below 120mmHg was associated with an increased
risk of cardiovascular deaths and congestive heart failure, but
not myocardial infarction in hypertensive type 2 diabetics.228
Finally, in the ACCORD study, while targeting a systolic
BP ofo120mmHg rather thano140mmHg did not reduce
cardiovascular outcomes, serious adverse events occurred in
3.3% of the lower BP group compared with 1.3% (po0.001)
in the higher BP target group indicating the potential penalty
paid for aggressive BP reduction.159
In CKD ND patients, there is observational evidence from
two community-based longitudinal studies including 1549
subjects with CKD 3-4. In one study, a J-shaped relationship
between stroke and systolic BP was observed, with lowest
stroke risk in the range of systolic BP between 120 and
129mmHg, and higher risk above and below this.158 A
cohort study of 860 US veterans (comprising mainly men)
with CKD (GFR o60 and a subset with GFR o30ml/min/
1.73 m2) showed greater mortality when systolic BP was
o133mmHg or diastolic BP o65mmHg, although it
appeared that the association might not be causal but instead
related to atherosclerotic CVD as a co-morbidity.413
In summary, with respect to a lowest BP target, most of
the relevant evidence is observational, derived from retro-
spective analyses, and nearly all involves non-CKD popula-
tions. No studies to date have specifically tested a strategy of
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reducing blood-pressure-lowering drug treatment if the BP
falls below a certain limit. We anticipate that there would be
major practical difficulties in implementing such a practice,
particularly in patients with reduced conduit artery com-
pliance and consequent increased pulse pressure (in whom a
lower limit for diastolic BP might entail accepting an systolic
BP much higher than the current targets). Although the
available evidence is enough to support our guideline
statements advising caution in those with co-morbidity, we
do not consider it is robust enough to allow us to specify a
lower limit for either systolic BP or diastolic BP, even though
other organizations have done so.396 Although inferences can
be drawn when treatment-related BP is too low, especially in
patients with diabetes, the elderly and those with CVD, we
are left without a lowest BP target.
The NIH funded SPRINT trial currently recruiting patients in
the US may clarify this issue. It will randomize over 7500 patients
with systolic BP to targets of o140mmHg or o120mmHg,
deliberately including approximately 1750 patients over 75, and
followed for cardiovascular, cognitive and kidney end points over
a period of 9 years, commencing 2010.171,172
8.3: SHOULD A REDUCTION IN ALBUMINURIA BE A TARGET
FOR TREATMENT WITH AGENTS THAT MODIFY BP?
As outlined elsewhere in this Guideline, RAAS intervention is
effective in not only lowering BP but also protecting
individual patients with CKD from further decline in kidney
function. Although the BP-lowering effect of RAAS inhibi-
tion contributes to renoprotection, a component of the
protective effect may be independent of the effect on BP.
Thus, to achieve maximum renoprotection using a RAAS
inhibitor, the clinician might consider monitoring the
reduction in urine albumin excretion (an ‘off target’ effect).
This is particularly important in macroalbuminuric and
microalbuminuric hypertensive subjects with type 2 diabetes,
in whom the BP response to RAAS inhibitors may be
discordant with the anti-albuminuric response.414,415 Studies
in such patients indicate that those in whom urine albumin
was lowered without significant lowering of BP gained some
renoprotection, whereas patients who did not have urine
albumin lowered in spite of BP-lowering did not have
renoprotection.414 Thus, albuminuria may be an independent
factor in renoprotection. In a prospective study supporting
this concept, Hou et al.416 detected nearly 50% additional
renoprotection with a dose of a RAAS inhibitor titrated to
maximally reduce urine albumin levels as compared to a
standard dose used for the BP lowering effect.
There have been no RCTs assessing hard renal or cardio-
vascular outcomes, in which patients have been randomized to
different targets of urinary albumin excretion irrespective of BP.
8.4: SHOULD RAAS INHIBITION BE MAXIMIZED IN CKD
PATIENTS?
Accepting that RAAS inhibitors may be used to both lower BP
and urine albumin excretion, options are available to optimize
the albuminuria lowering effect of these agents. For example, it
is well recognized that co-administration of a low-sodium
diet417,418 or the addition of a diuretic63,66,419 enhances the
effect of both ACE-Is and ARBs on lowering urine albumin
excretion. Such therapeutic combinations make good sense
and are unlikely to be associated with harmful side effects.
Whether more aggressive blockade of the RAAS using
supramaximal doses of ACE-Is or ARBs is beneficial is less
certain. Recently, Burgess et al.420 showed that increasing the
dose of candesartan well beyond the guideline-recommended
dose for BP-lowering resulted in further reduction of the
urine albumin levels.
The substantial evidence suggesting that RAAS inhibition
using ACE-Is or ARBs has renoprotective effects when these
agents are used individually has led to the hypothesis that
combining the two classes of agents, or adding an aldosterone
antagonist or a DRI, may provide additional benefit. Interest in
this approach has been increased by the evidence that individuals
treated with ACE-Is may have ‘aldosterone breakthrough’89 with
angiotensin I to angiotensin II conversion occurring via other
pathways421 and by the fact that there may be other active
receptors for angiotensin II422 that may have a range of roles.
A number of moderate-sized studies, mostly in patients
with diabetes, have demonstrated that proteinuria levels may
be further lowered by combining ACE-Is and ARBs than by
using each agent alone.423 Aldosterone antagonists may
substantially lower proteinuria when used on top of ACE-Is
or ARBs.424 Similarly when the DRI, aliskiren, was added to
an ARB,112 proteinuria was reduced.
The optimism generated by these findings has recently been
seriously dampened. The ONTARGET trial did not demonstrate
any cardiovascular benefit for dual RAAS blockade (with the
ACE-I ramipril and the ARB telmisartan), in a population at
high risk of CVD, but did suggest an increased risk of major
renal outcomes with dual RAAS blockade.281 This finding has
been questioned for a range of reasons, and it has been
suggested that the result may have been different if the
population included a greater number of patients with CKD.425
The ALTITUDE trial randomized type 2 diabetic partici-
pants to receive either aliskiren or matching placebo on top
of an ACE-I or ARB113 and included a large number of
diabetic individuals with CKD.426 Although the results have
not been published at the time of writing this Guideline, the
trial was recently stopped early due to a low likelihood of ever
demonstrating benefit and a suggestion of an increased risk
of some adverse outcomes, including non-fatal stroke, renal
complications, hyperkalemia and hypotension,427 resulting in
the US FDA counselling against this practice.114
As a result, any benefits of combined blockade of the
RAAS for clinically important renal outcomes currently
remain unproven, and the safety issues should be taken into
account prior to using this therapeutic approach.
8.5: SHOULD ACE-IS AND ARBS BE DISCONTINUED IN CKD 5
BECAUSE THEY COMPROMISE RESIDUAL KIDNEY FUNCTION?
It has long been recognized that commencing ACE-Is and
ARBs can lead to an acute reduction in GFR that may be
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reversed if the dose is reduced or if the drug is discontinued.
This phenomenon has been observed in the context of RCTs
such as the RENAAL trial. In a post hoc analysis of this study,
an initial fall in GFR was found to predict better long-term
renoprotection.87 Such acute changes in GFR are likely to
reflect the hemodynamic changes that accompany initiation
of RAAS blockade.88,428 However, since a reduction in GFR is
not usually considered beneficial, observers have recently
questioned the value of commencing or continuing BP-
lowering regimens based on an ACE-I or ARB in elderly
patients with advanced CKD and have specifically suggested
that use of such agents in CKD 4–5 patients may compromise
residual kidney function or even accelerate its rate of decline
in both diabetic429 and non-diabetic patients.430
This opinion is based on uncontrolled observations and is
contrary to the observations made from the RENAAL RCT in
patients approaching renal replacement therapy.431 For
example in one such observational study, discontinuation
of ACE-Is and ARBs in 52 patients with CKD 4–5 was
followed by a greater than 25% increase in the GFR in 61.5%
of patients, and a greater than 50% increase in 36.5% of
patients.23 An RCT that specifically randomized patients with
advanced CKD to benzapril or placebo did not support
this.192 The study reported that 112 predominantly CKD 4
patients with a mean GFR of 26ml/min/1.73 m2 receiving
benzapril had a lower risk of doubling of SCr, kidney failure,
or death compared with the same number of patients
receiving placebo. A small study of 60 peritoneal dialysis
patients showed better preservation of residual kidney
function among patients randomized to ramipril as com-
pared to no treatment.432
Thus, the current evidence does not support the
discontinuing ACE-Is and ARBs in patients with advanced
CKD in an effort to preserve residual kidney function,
although hyperkalemia or hypotension may be a specific
reason for discontinuation in some patients.
8.6: ETHNICITY, RACE, AND GENES
In this Guideline, the individualization of BP control is
emphasized, yet specific advice to tailor therapy according to
ethnicity, race, or genetic influences is not available. In lieu of
such advice, we have drawn on RCTs specific to various racial
and ethnic populations: African-American, Chinese, Japa-
nese, Pakistani, and European whites (sometimes from a
single country). We have generalized the observations derived
from these ethnicity- or race-specific RCTs to management
advice applicable to all ethnic and racial groups. However,
there is good reason—but not good evidence—to believe that
ethnicity, race, and genotype influence elevated BP and CKD,
with familial aggregation and ethnic–racial disparities in both
conditions. Currently, it is difficult to disentangle ethnic–-
racial disparities from social, economic, and environmental
disparities.
The evidence for ethnic or racial influence on CKD is
mainly epidemiological. The incidence of kidney failure
requiring dialysis is higher in a wide variety of non-white
groups (African-American, Asian, Native American, Native
Australian, and Pacific Islander) than in white groups of
European heritage in North America, Europe, and the
Asia–Pacific region.366,433–435 Hypertension is also more
common, develops earlier in life, and manifests with a higher
average BP among African-Americans than whites in the
United States.436
Although profound environmental and socioeconomic
issues are clearly involved, information is gradually being
gathered that enlightens us about some of the links among
genetics, high BP and kidney disease in the African-American
population.437 Genetic variance in the non-muscle myosin
heavy chain 9 gene (MYH9) was reported to be partly
responsible for progressive kidney disease in hypertensive
African-Americans.438 This might provide a rationale for
lower BP targets in hypertensive African-Americans than
other racial groups,439 especially in African-Americans with
genetic variation in the MYH9 gene. More recently,
polymorphisms in the apolipoprotein L-1 gene (APOL1),
which is located immediately upstream to MYH9, has been
implicated in this process, with the APOLI G1 and G2 alleles
associating with focal segmental glomerulosclerosis in
African-Americans.440 Intriguingly, these variants seem to
confer resistance to Trypanosoma brucei rhodesiense, which
may explain the persistence of this seemingly otherwise
disadvantageous gene in West Africans, but this hypothesis
does not clarify the association between APOL1 and focal
segmental glomerulosclerosis.
Epidemiological evidence is suggestive of many other
ethnic–racial differences among individuals with CKD. In
addition to the differences in the prevalence of types of
kidney diseases in different groups, there appear to be
differences in the rates of CKD progression, in the effects of
BP control on CKD progression, in BP responses to various
antihypertensive regimens, and in cardiovascular risk asso-
ciated with a particular BP level. Outlining this evidence is
beyond the scope of this Guideline, but clearly the scientific
community is currently only scratching the surface of the
links among BP, CKD, race, ethnicity, genes, and epigenetics.
In the future evidence may become available regarding how
to modify BP control in CKD according to an individual’s
genetic profile, or ethnic or racial background. In the
meantime, we must pay greater attention to socioeconomic
and environmental issues related to ethnicity or race, which
are more immediately amenable to modification.
8.7: BARRIERS TO IMPLEMENTATION
Although several guidelines on BP management in CKD have
been published, BP management in CKD patients is often
suboptimal and audit studies suggest that the target readings
are not achieved in many patients.441 The reasons why it is
challenging to implement recommendations and to achieve
target BP in CKD (and other) patient populations are
multiple and complex, but are likely to include the issues
listed below. Because of these uncertainties we cannot suggest
that the recommended BP targets in this Guideline should be
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used as performance measures in the management of CKD
patients.
The credibility of the guideline is questioned. Not all
clinicians agree with the currently recommended BP targets,
at least not for all of their patients. The evidence supporting
current BP targets in CKD has been challenged, reinforcing
clinicians’ concerns.22 However, surveys have shown that less
stringent BP targets, such as 160/90mmHg, are also not
regularly achieved.441 The BP targets recommended in this
guideline are higher than those in some previous publications
and it remains to be seen whether this will result in a higher
proportion of CKD patients achieving them.
The trial data are not directly relevant to a real world
setting. There are few systematically collected data to support
the notion that BP control cannot be achieved in most patients.
However several important issues need to be considered when
extrapolating from clinical trials to a ‘real world’ setting. Firstly,
patients recruited into RCTs are selected for characteristics that
increase the likelihood of BP control. These include a lack of
co-morbidities, an absence of previous adverse reactions to the
BP-modifying agents used in the trial, good BP control during
a run-in or washout period and high motivation, reflected by
the patients’ willingness to enroll. Secondly, patients partici-
pating in trials are often micro-managed in specialized clinics,
where frequent reinforcement and pill-counting increases the
likelihood of adherence to the drug regimen. Thirdly, patients
who drop out because of drug-related side effects or non-
adherence are usually accounted for in intention-to-treat
analyses and the overall proportion of dropouts is not often
reported (although may be 10% or more of the recruited
population). Finally, although the mean achieved BP is often
close to the intended target, the SD of the reported BP
measurements is often large, suggesting that the recorded
values in many patients are well above the mean and hence well
above the target.22 Only rarely is the actual number of patients
not achieving the target BP reported. Taken together, these
factors indicate that the proportion of patients with CKD in
whom BP cannot be controlled to a specified target may be
much higher than indicated by the data derived from RCTs.
Patients do not adhere to the treatment. The reasons why
patients do or do not adhere to medical advice are believed to
depend in part on cost–benefit analysis by the patients
themselves. This is particularly relevant to the use of BP-
modifying drugs that do not provide immediately perceivable
improvement in quality of life or relief of symptoms, yet have
immediately observable negative effects in terms of expense
and inconvenience, even if there are no adverse side effects.
The literature contains many reports of poor adherence to
BP-modifying drug regimens and suboptimal BP control in
CKD patients is known to be associated with poor adherence
to medication.442
BP fluctuates. In a usual clinical setting, if a BP target is
set, a clinician will gradually increase the number of drugs
prescribed to a given patient until this target is achieved. The
regimen will not then be altered again unless several BP
readings are above (sometimes well above) that target.
Because BP fluctuates, there is a good chance that a
proportion of the subsequent BP readings will inevitably be
above a previously achieved target. One way to circumvent
this problem is to set a threshold level for treatment that is
lower than the desired target. This strategy has been used in
several health care recommendations, including the WHO
nutrition goals and the 1997 NKF–Dialysis Outcomes Quality
Initiative Hemodialysis Adequacy guideline. As previously
stated and in line with several previous guidelines on BP
management in CKD, we have set the same values for the
threshold for treatment and desired target systolic and
diastolic levels. We emphasize the value of checking for
consistency by using repeated BP measurements to direct
therapy and believe that this strategy will improve target
attainment.
BP is measured infrequently. Traditionally, BP control is
audited by measuring the BP in a patient or a group of
patients on just one occasion. In an individual patient,
the BP can be better assessed by means of repeated
clinical measurements over a period of time or by more
sophisticated techniques such as home self-measurement of
BP or ABPM. Evaluating guideline implementation in a
group of patients is difficult, as repeated or more sophisti-
cated measurements are not possible in everyone. We have
insufficient knowledge of what proportion of patients at any
one time will have a BP level above the target value, even
when guidelines have been closely followed and adherence
has been high. In a post hoc analysis of a large RCTof essential
hypertension, a single elevated office BP reading in a patient
with previously well controlled BP was unlikely to indicate a
persistent loss of BP control, but rather reflect day-to-day
variation.443
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